Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors
- 1 August 2014
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in Anti-Cancer Drugs
- Vol. 25 (7), 841-847
- https://doi.org/10.1097/cad.0000000000000100
Abstract
An appreciable percentage of patients with relapsed/refractory germ-cell tumors (GCTs), candidates for high-dose chemotherapy (HDC) and autologous hematopoietic cell transplantation (HCT), fail to mobilize adequate hematopoietic stem cells (HSCs) numbers with granulocyte colony-stimulating factor (G-CSF)±salvage chemotherapy. Plerixafor has shown a potential to mobilize adequate CD34+HSCs numbers in this context. Here, we applied plerixafor in combination with G-CSF after salvage chemotherapy in ‘poor’ mobilizers with relapsed/refractory GCTs for HDC+HCT. Patients with relapsed/refractory GCTs (n=10) received salvage paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy+G-CSF to mobilize adequate HSCs to support HDC, mainly with two courses of high-dose thiotepa-etoposide-carboplatin (TEC). Patients failing to achieve the minimum collection threshold of 2.0×106/kg CD34+ cells, to support at least one cycle of HDC, were administered plerixafor before the anticipated HSC collection during subsequent cycle(s). Overall, seven patients mobilized adequate CD34+ cells (>5.0×106/kg) aiming to support two cycles of HDC. Three patients did not mobilize adequate numbers of CD34+ cells after previous G-CSF plus salvage TIP, and plerixafor was added in subsequent cycle(s). This led to a collection of adequate CD34+ cells, able to support HDC with TEC (1–2 cycles). Hematopoietic engraftment for neutrophils (absolute neutrophil count>500/μl) and platelets (platelet count>20 000/μl) with plerixafor-mobilized HSCs occurred after a median of 9 and 14 days, respectively. Salvage TIP+G-CSF leads to successful HSC mobilization in patients with less heavily pretreated GCTs, whereas the addition of plerixafor to G-CSF+TIP led to mobilization of adequate HSCs that supported autografting after one to two TEC cycles.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumorsBone Marrow Transplantation, 2012
- How I treat patients who mobilize hematopoietic stem cells poorlyBlood, 2011
- Plerixafor Enables Successful Hematopoietic Stem Cell Collection in an Extensively Pretreated Patient with Testicular CancerActa Haematologica, 2010
- Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumorHematology/Oncology and Stem Cell Therapy, 2010
- Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilizationBone Marrow Transplantation, 2010
- Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphomaBone Marrow Transplantation, 2010
- Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaBlood, 2009
- High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell TumorsThe New England Journal of Medicine, 2007
- Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factorBlood, 1993
- Regimen-related toxicity in patients undergoing bone marrow transplantation.Journal of Clinical Oncology, 1988